Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes
To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS). We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2003-05, Vol.21 (10), p.1988-1995 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1995 |
|---|---|
| container_issue | 10 |
| container_start_page | 1988 |
| container_title | Journal of clinical oncology |
| container_volume | 21 |
| creator | CILLONI, Daniela GOTTARDI, Enrico LEVIS, Alessandro SAGLIO, Giuseppe MESSA, Francesca FAVA, Milena SCARAVAGLIO, Patrizia BERTINI, Marilena GIROTTO, Mauro MARINONE, Carlo FERRERO, Dario GALLAMINI, Andrea |
| description | To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS).
We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction (RQ-PCR) in 173 samples (131 bone marrow samples and 42 peripheral-blood samples) from 131 patients with MDS (79 patients with refractory anemia [RA], 31 with RA with excess blasts [RAEB], 18 with secondary acute myeloid leukemia [s-AML] evolved from MDS, and three with deletion of 5q as the sole cytogenetic abnormality). Values obtained were correlated with the blast percentage and International Prognostic Scoring System (IPSS) score.
Sixty-five percent of BM and 78% of PB samples for RA and 100% of BM and PB samples of RAEB and s-AML expressed WT1 transcript amounts greater than the level observed in healthy volunteers. The degree of WT1 expression was highly correlated with the type of MDS, was much higher in RAEB and s-AML compared with RA, and increased during disease progression. Moreover, a significant correlation was found between WT1 expression levels, blast cell percentage, and the presence of cytogenetic abnormalities. Therefore, we found a significant correlation between the amount of WT1 transcripts and the IPSS score, which currently represents the most reliable risk index of disease progression available for MDS patients.
WT1 is a useful molecular marker for risk assessment in MDS patients. |
| doi_str_mv | 10.1200/JCO.2003.10.503 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73282033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73282033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-96a31d623257177dde9b2cbd5827dc2331972523bbaf6235bd25323ecdca80c03</originalsourceid><addsrcrecordid>eNpFkc1uEzEURi0EoqGwZoe8AVaT-ieOJ0sIBYqKWilFZTfy2Hcmrjx2sB2VeRjeFU8SqasrX53v05UPQm8pmVNGyMWP9c28TD4vC0H4MzSjgslKSiGeoxmRnFW05r_P0KuUHgihi5qLl-iMMrngVPAZ-rexvbed1cpnvA4xglPZBo8_Q34E8DhvAX-BPgLg0OH7O4ov_-4ipDRBypsDcOUzRH8IKodvY-h9SNlqvNEhWt_jzZgyDIcnYOvxbWHB54Tvbd7inyO4YMa0c-qYGr2JYYD0Gr3olEvw5jTP0a-vl3fr79X1zber9afrSnMhcrVaKk7NknEmJJXSGFi1TLdG1EwazTinK8kE422rukKJ1jDBGQdttKqJJvwcfTj27mL4s4eUm8EmDc4pD2GfmvKPNSOcF_DiCOoYUorQNbtoBxXHhpJmMtIUI81kZFoUIyXx7lS9bwcwT_xJQQHenwCVtHJdVF7b9MQtarakYrrx45Hb2n77aCM0aVDOlVrWPOjA6OGEVV3z_y8ao3o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73282033</pqid></control><display><type>article</type><title>Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>CILLONI, Daniela ; GOTTARDI, Enrico ; LEVIS, Alessandro ; SAGLIO, Giuseppe ; MESSA, Francesca ; FAVA, Milena ; SCARAVAGLIO, Patrizia ; BERTINI, Marilena ; GIROTTO, Mauro ; MARINONE, Carlo ; FERRERO, Dario ; GALLAMINI, Andrea</creator><creatorcontrib>CILLONI, Daniela ; GOTTARDI, Enrico ; LEVIS, Alessandro ; SAGLIO, Giuseppe ; MESSA, Francesca ; FAVA, Milena ; SCARAVAGLIO, Patrizia ; BERTINI, Marilena ; GIROTTO, Mauro ; MARINONE, Carlo ; FERRERO, Dario ; GALLAMINI, Andrea ; Piedmont Study Group on Myleodysplastic Syndromes</creatorcontrib><description>To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS).
We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction (RQ-PCR) in 173 samples (131 bone marrow samples and 42 peripheral-blood samples) from 131 patients with MDS (79 patients with refractory anemia [RA], 31 with RA with excess blasts [RAEB], 18 with secondary acute myeloid leukemia [s-AML] evolved from MDS, and three with deletion of 5q as the sole cytogenetic abnormality). Values obtained were correlated with the blast percentage and International Prognostic Scoring System (IPSS) score.
Sixty-five percent of BM and 78% of PB samples for RA and 100% of BM and PB samples of RAEB and s-AML expressed WT1 transcript amounts greater than the level observed in healthy volunteers. The degree of WT1 expression was highly correlated with the type of MDS, was much higher in RAEB and s-AML compared with RA, and increased during disease progression. Moreover, a significant correlation was found between WT1 expression levels, blast cell percentage, and the presence of cytogenetic abnormalities. Therefore, we found a significant correlation between the amount of WT1 transcripts and the IPSS score, which currently represents the most reliable risk index of disease progression available for MDS patients.
WT1 is a useful molecular marker for risk assessment in MDS patients.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2003.10.503</identifier><identifier>PMID: 12743153</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - metabolism ; Bone Marrow - metabolism ; Case-Control Studies ; Disease Progression ; DNA Primers ; Flow Cytometry ; Gene Expression Regulation, Neoplastic ; Hematologic and hematopoietic diseases ; Humans ; Immunophenotyping ; Leukemia, Myeloid - diagnosis ; Leukemia, Myeloid - genetics ; Leukemia, Myeloid - metabolism ; Leukemia, Myeloid - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Myelodysplastic Syndromes - diagnosis ; Myelodysplastic Syndromes - genetics ; Myelodysplastic Syndromes - metabolism ; Myelodysplastic Syndromes - pathology ; Polymerase Chain Reaction ; Prognosis ; Regression Analysis ; WT1 Proteins - blood ; WT1 Proteins - metabolism</subject><ispartof>Journal of clinical oncology, 2003-05, Vol.21 (10), p.1988-1995</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-96a31d623257177dde9b2cbd5827dc2331972523bbaf6235bd25323ecdca80c03</citedby><cites>FETCH-LOGICAL-c355t-96a31d623257177dde9b2cbd5827dc2331972523bbaf6235bd25323ecdca80c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14826150$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12743153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CILLONI, Daniela</creatorcontrib><creatorcontrib>GOTTARDI, Enrico</creatorcontrib><creatorcontrib>LEVIS, Alessandro</creatorcontrib><creatorcontrib>SAGLIO, Giuseppe</creatorcontrib><creatorcontrib>MESSA, Francesca</creatorcontrib><creatorcontrib>FAVA, Milena</creatorcontrib><creatorcontrib>SCARAVAGLIO, Patrizia</creatorcontrib><creatorcontrib>BERTINI, Marilena</creatorcontrib><creatorcontrib>GIROTTO, Mauro</creatorcontrib><creatorcontrib>MARINONE, Carlo</creatorcontrib><creatorcontrib>FERRERO, Dario</creatorcontrib><creatorcontrib>GALLAMINI, Andrea</creatorcontrib><creatorcontrib>Piedmont Study Group on Myleodysplastic Syndromes</creatorcontrib><title>Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS).
We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction (RQ-PCR) in 173 samples (131 bone marrow samples and 42 peripheral-blood samples) from 131 patients with MDS (79 patients with refractory anemia [RA], 31 with RA with excess blasts [RAEB], 18 with secondary acute myeloid leukemia [s-AML] evolved from MDS, and three with deletion of 5q as the sole cytogenetic abnormality). Values obtained were correlated with the blast percentage and International Prognostic Scoring System (IPSS) score.
Sixty-five percent of BM and 78% of PB samples for RA and 100% of BM and PB samples of RAEB and s-AML expressed WT1 transcript amounts greater than the level observed in healthy volunteers. The degree of WT1 expression was highly correlated with the type of MDS, was much higher in RAEB and s-AML compared with RA, and increased during disease progression. Moreover, a significant correlation was found between WT1 expression levels, blast cell percentage, and the presence of cytogenetic abnormalities. Therefore, we found a significant correlation between the amount of WT1 transcripts and the IPSS score, which currently represents the most reliable risk index of disease progression available for MDS patients.
WT1 is a useful molecular marker for risk assessment in MDS patients.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Bone Marrow - metabolism</subject><subject>Case-Control Studies</subject><subject>Disease Progression</subject><subject>DNA Primers</subject><subject>Flow Cytometry</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Leukemia, Myeloid - diagnosis</subject><subject>Leukemia, Myeloid - genetics</subject><subject>Leukemia, Myeloid - metabolism</subject><subject>Leukemia, Myeloid - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Myelodysplastic Syndromes - diagnosis</subject><subject>Myelodysplastic Syndromes - genetics</subject><subject>Myelodysplastic Syndromes - metabolism</subject><subject>Myelodysplastic Syndromes - pathology</subject><subject>Polymerase Chain Reaction</subject><subject>Prognosis</subject><subject>Regression Analysis</subject><subject>WT1 Proteins - blood</subject><subject>WT1 Proteins - metabolism</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc1uEzEURi0EoqGwZoe8AVaT-ieOJ0sIBYqKWilFZTfy2Hcmrjx2sB2VeRjeFU8SqasrX53v05UPQm8pmVNGyMWP9c28TD4vC0H4MzSjgslKSiGeoxmRnFW05r_P0KuUHgihi5qLl-iMMrngVPAZ-rexvbed1cpnvA4xglPZBo8_Q34E8DhvAX-BPgLg0OH7O4ov_-4ipDRBypsDcOUzRH8IKodvY-h9SNlqvNEhWt_jzZgyDIcnYOvxbWHB54Tvbd7inyO4YMa0c-qYGr2JYYD0Gr3olEvw5jTP0a-vl3fr79X1zber9afrSnMhcrVaKk7NknEmJJXSGFi1TLdG1EwazTinK8kE422rukKJ1jDBGQdttKqJJvwcfTj27mL4s4eUm8EmDc4pD2GfmvKPNSOcF_DiCOoYUorQNbtoBxXHhpJmMtIUI81kZFoUIyXx7lS9bwcwT_xJQQHenwCVtHJdVF7b9MQtarakYrrx45Hb2n77aCM0aVDOlVrWPOjA6OGEVV3z_y8ao3o</recordid><startdate>20030515</startdate><enddate>20030515</enddate><creator>CILLONI, Daniela</creator><creator>GOTTARDI, Enrico</creator><creator>LEVIS, Alessandro</creator><creator>SAGLIO, Giuseppe</creator><creator>MESSA, Francesca</creator><creator>FAVA, Milena</creator><creator>SCARAVAGLIO, Patrizia</creator><creator>BERTINI, Marilena</creator><creator>GIROTTO, Mauro</creator><creator>MARINONE, Carlo</creator><creator>FERRERO, Dario</creator><creator>GALLAMINI, Andrea</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030515</creationdate><title>Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes</title><author>CILLONI, Daniela ; GOTTARDI, Enrico ; LEVIS, Alessandro ; SAGLIO, Giuseppe ; MESSA, Francesca ; FAVA, Milena ; SCARAVAGLIO, Patrizia ; BERTINI, Marilena ; GIROTTO, Mauro ; MARINONE, Carlo ; FERRERO, Dario ; GALLAMINI, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-96a31d623257177dde9b2cbd5827dc2331972523bbaf6235bd25323ecdca80c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Bone Marrow - metabolism</topic><topic>Case-Control Studies</topic><topic>Disease Progression</topic><topic>DNA Primers</topic><topic>Flow Cytometry</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Leukemia, Myeloid - diagnosis</topic><topic>Leukemia, Myeloid - genetics</topic><topic>Leukemia, Myeloid - metabolism</topic><topic>Leukemia, Myeloid - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Myelodysplastic Syndromes - diagnosis</topic><topic>Myelodysplastic Syndromes - genetics</topic><topic>Myelodysplastic Syndromes - metabolism</topic><topic>Myelodysplastic Syndromes - pathology</topic><topic>Polymerase Chain Reaction</topic><topic>Prognosis</topic><topic>Regression Analysis</topic><topic>WT1 Proteins - blood</topic><topic>WT1 Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CILLONI, Daniela</creatorcontrib><creatorcontrib>GOTTARDI, Enrico</creatorcontrib><creatorcontrib>LEVIS, Alessandro</creatorcontrib><creatorcontrib>SAGLIO, Giuseppe</creatorcontrib><creatorcontrib>MESSA, Francesca</creatorcontrib><creatorcontrib>FAVA, Milena</creatorcontrib><creatorcontrib>SCARAVAGLIO, Patrizia</creatorcontrib><creatorcontrib>BERTINI, Marilena</creatorcontrib><creatorcontrib>GIROTTO, Mauro</creatorcontrib><creatorcontrib>MARINONE, Carlo</creatorcontrib><creatorcontrib>FERRERO, Dario</creatorcontrib><creatorcontrib>GALLAMINI, Andrea</creatorcontrib><creatorcontrib>Piedmont Study Group on Myleodysplastic Syndromes</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CILLONI, Daniela</au><au>GOTTARDI, Enrico</au><au>LEVIS, Alessandro</au><au>SAGLIO, Giuseppe</au><au>MESSA, Francesca</au><au>FAVA, Milena</au><au>SCARAVAGLIO, Patrizia</au><au>BERTINI, Marilena</au><au>GIROTTO, Mauro</au><au>MARINONE, Carlo</au><au>FERRERO, Dario</au><au>GALLAMINI, Andrea</au><aucorp>Piedmont Study Group on Myleodysplastic Syndromes</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2003-05-15</date><risdate>2003</risdate><volume>21</volume><issue>10</issue><spage>1988</spage><epage>1995</epage><pages>1988-1995</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS).
We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction (RQ-PCR) in 173 samples (131 bone marrow samples and 42 peripheral-blood samples) from 131 patients with MDS (79 patients with refractory anemia [RA], 31 with RA with excess blasts [RAEB], 18 with secondary acute myeloid leukemia [s-AML] evolved from MDS, and three with deletion of 5q as the sole cytogenetic abnormality). Values obtained were correlated with the blast percentage and International Prognostic Scoring System (IPSS) score.
Sixty-five percent of BM and 78% of PB samples for RA and 100% of BM and PB samples of RAEB and s-AML expressed WT1 transcript amounts greater than the level observed in healthy volunteers. The degree of WT1 expression was highly correlated with the type of MDS, was much higher in RAEB and s-AML compared with RA, and increased during disease progression. Moreover, a significant correlation was found between WT1 expression levels, blast cell percentage, and the presence of cytogenetic abnormalities. Therefore, we found a significant correlation between the amount of WT1 transcripts and the IPSS score, which currently represents the most reliable risk index of disease progression available for MDS patients.
WT1 is a useful molecular marker for risk assessment in MDS patients.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>12743153</pmid><doi>10.1200/JCO.2003.10.503</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2003-05, Vol.21 (10), p.1988-1995 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73282033 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Biological and medical sciences Biomarkers, Tumor - blood Biomarkers, Tumor - metabolism Bone Marrow - metabolism Case-Control Studies Disease Progression DNA Primers Flow Cytometry Gene Expression Regulation, Neoplastic Hematologic and hematopoietic diseases Humans Immunophenotyping Leukemia, Myeloid - diagnosis Leukemia, Myeloid - genetics Leukemia, Myeloid - metabolism Leukemia, Myeloid - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - metabolism Myelodysplastic Syndromes - pathology Polymerase Chain Reaction Prognosis Regression Analysis WT1 Proteins - blood WT1 Proteins - metabolism |
| title | Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A53%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Significant%20Correlation%20Between%20the%20Degree%20of%20WT1%20Expression%20and%20the%20International%20Prognostic%20Scoring%20System%20Score%20in%20Patients%20With%20Myelodysplastic%20Syndromes&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=CILLONI,%20Daniela&rft.aucorp=Piedmont%20Study%20Group%20on%20Myleodysplastic%20Syndromes&rft.date=2003-05-15&rft.volume=21&rft.issue=10&rft.spage=1988&rft.epage=1995&rft.pages=1988-1995&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2003.10.503&rft_dat=%3Cproquest_cross%3E73282033%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73282033&rft_id=info:pmid/12743153&rfr_iscdi=true |